The Transgenic Mouse Shared Resource is a fully Cancer Center-managed facility. The generation and use oftransgenic and gene-targeted mice is an essential technology for basic cancer research. Since its establishmentin 1995 the Transgenic Mouse Shared Resource has served to make transgenic technologies accessible to allCancer Center members, which has had a major impact on the quality and quantity of cancer research usinggenetically modified mouse models. The resource has served over 80 different investigators over the past threeyears, and has generated hundreds of new strains of transgenic and gene-targeted mice.The services provided by the Transgenic Mouse Shared Resource are: Production of transgenic mice by pronuclear DMA microinjection and embryo transfer; Production of chimeric mice by blastocyst injection of genetically modified ES cells and embryo transfer,which is part of the procedure of producing knockout or knockin mice; and Gene targeting, which involves the electroporation of a targeting vector into pluripotent mouse embryonicstem (ES) cells and the selection of gene-targeted clones; Education of investigators and advice on vector and experimental design for experiments usingtransgenic and knockout mice.The facility maintains a library of vectors and genes that are generally useful for the construction of transgenesand targeting vectors. In the future, to supplement these now standard transgenic methods, we plan to establisha service that will use 'BAG recombineering' to efficiently produce large-insert gene targeting vectors andtransgenes. Beyond these specific fee-based services, the Resource provides free advice and consultation onall aspects of the design, generation, breeding and analysis of genetically modified mouse models. The Director(Dr. Frank Costantini), Co-Director (Dr. Thomas Ludwig) and Manager (Dr. Chyuan-Sheng Lin) of the facilitycollectively have many decades of experience in numerous aspects of mouse genetics, transgenic mo'usetechnology, and the use of mouse models in cancer research, and their expertise has contributed greatly to theexcellence of transgenic mouse research at Columbia. During the last period of the CCSG, 51% of theinvestigators using the facility were Cancer Center members with peer-reviewed funding, with those membersrepresenting from 53% to 78% of the usage of the 3 available services. The proposed total operating budget ofthe facility is $531,018 for the Transgenic Mouse Shared Resource, of which we are requesting $183,948 fromthe CGSG. In addition, mouse cage costs managed by the Institute for Comparative Medicine are $324,111, ofwhich we are requesting $135,771 from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA013696-35
Application #
7669922
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-08-01
Project End
2013-06-30
Budget Start
2008-08-01
Budget End
2009-06-30
Support Year
35
Fiscal Year
2008
Total Cost
$281,053
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Sones, Jennifer L; Merriam, Audrey A; Seffens, Angelina et al. (2018) Angiogenic factor imbalance precedes complement deposition in placentae of the BPH/5 model of preeclampsia. FASEB J 32:2574-2586
Park, Karen Sophia; Xu, Christine L; Cui, Xuan et al. (2018) Reprogramming the metabolome rescues retinal degeneration. Cell Mol Life Sci 75:1559-1566
Mumau, Melanie D; Vanderbeck, Ashley N; Lynch, Elizabeth D et al. (2018) Identification of a Multipotent Progenitor Population in the Spleen That Is Regulated by NR4A1. J Immunol 200:1078-1087
Savage, Thomas M; Shonts, Brittany A; Obradovic, Aleksandar et al. (2018) Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight 3:
Caviglia, Jorge Matias; Yan, Jun; Jang, Myoung-Kuk et al. (2018) MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology 67:2414-2429
Jauregui, Ruben; Park, Karen Sophia; Tsang, Stephen H (2018) Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa. Ophthalmic Genet 39:544-549
Wu, Wen-Hsuan; Tsai, Yi-Ting; Justus, Sally et al. (2018) CRISPR Repair Reveals Causative Mutation in a Preclinical Model of Retinitis Pigmentosa: A Brief Methodology. Methods Mol Biol 1715:191-205
Yen, Bonnie; Fortson, Katherine T; Rothman, Nyanza J et al. (2018) Clonal Bifurcation of Foxp3 Expression Visualized in Thymocytes and T Cells. Immunohorizons 2:119-128
Ishida, Chiaki T; Zhang, Yiru; Bianchetti, Elena et al. (2018) Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma. Clin Cancer Res 24:5392-5406
Jin, Chun-Hui; Li, Yang; Xia, Jinxing et al. (2018) CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion. Am J Hematol 93:786-793

Showing the most recent 10 out of 331 publications